John Volpone - 12 Aug 2026 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: President
Issuer ticker: XFOR
Reported as of: 12 Aug 2026
Net transaction value: -$109,228
SEC form: 4
Accepted by SEC: 13 Aug 2026, 16:13:03 UTC
Prior SEC filing: 31 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ David Kirske, Attorney-In-Fact

Key filing fact

John Volpone filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 13 Aug 2026.

Key facts

This page summarizes John Volpone's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Aug 2026, 16:13.

Change

Previous filing in this sequence was filed on 31 Oct 2025.
Current net transaction value: -$109,228.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002081729 Primary reporting owner

Volpone John

Relationship: President
Address: C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON
Signature: /s/ David Kirske, Attorney-In-Fact
Signature date: 13 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XFOR transaction

Common Stock

Sale

Transaction value: $109,228
Shares: -24,576
Change %: -8.5%
Price: $4.44
Shares after: 265,305
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.33 to $4.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

Of the shares of common stock reported, 193,254 shares represent restricted stock units.